
-
bluebird bio NasdaqGS:BLUE bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
Location: 455 Grand Union Boulevard, Somerville, MA, 02145, United States | Website: https://www.bluebirdbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
186.9M
Cash
78.74M
Avg Qtr Burn
-57.2M
Short % of Float
2.89%
Insider Ownership
0.71%
Institutional Own.
39.71%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYFGENIA (Lovo-cel) (LentiGlobin) (bb1111) Details Sickle cell disease | Approved Quarterly sales | |
SKYSONA (eli-cel) (Lenti-D) Details cerebral adrenoleukodystrophy | Approved Quarterly sales | |
ABECMA (ide-cel) (bb2121) Details Multiple myeloma | Approved Quarterly sales | |
ZYNTEGLO (beti-cel) Details Beta thalessemia | Approved Quarterly sales | |
Lovo-cel Details Sickle cell disease | Phase 3 Data readout |